These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
261 related articles for article (PubMed ID: 36384351)
21. Clinical approval of nanotechnology-based SARS-CoV-2 mRNA vaccines: impact on translational nanomedicine. Milane L; Amiji M Drug Deliv Transl Res; 2021 Aug; 11(4):1309-1315. PubMed ID: 33512669 [TBL] [Abstract][Full Text] [Related]
22. mRNA vaccines: the most recent clinical applications of synthetic mRNA. Kwon S; Kwon M; Im S; Lee K; Lee H Arch Pharm Res; 2022 Apr; 45(4):245-262. PubMed ID: 35426547 [TBL] [Abstract][Full Text] [Related]
23. Immunogenicity mechanism of mRNA vaccines and their limitations in promoting adaptive protection against SARS-CoV-2. Salleh MZ; Norazmi MN; Deris ZZ PeerJ; 2022; 10():e13083. PubMed ID: 35287350 [TBL] [Abstract][Full Text] [Related]
24. Vaccines 'on demand': science fiction or a future reality. Ulmer JB; Mansoura MK; Geall AJ Expert Opin Drug Discov; 2015 Feb; 10(2):101-6. PubMed ID: 25582273 [TBL] [Abstract][Full Text] [Related]
25. The Importance of RNA-Based Vaccines in the Fight against COVID-19: An Overview. Machado BAS; Hodel KVS; Fonseca LMDS; Mascarenhas LAB; Andrade LPCDS; Rocha VPC; Soares MBP; Berglund P; Duthie MS; Reed SG; Badaró R Vaccines (Basel); 2021 Nov; 9(11):. PubMed ID: 34835276 [TBL] [Abstract][Full Text] [Related]
26. mRNA based vaccines provide broad protection against different SARS-CoV-2 variants of concern. Wang H; Chen Z; Wang Z; Li J; Yan Z; Yuan J; Zhu A; Chen L; Liu Y; Hu C; Zhu A; Li G; Li Y; Deng J; Ma L; Sui X; Miao W; Li J; Zheng X; Piao J; Yao Y; Rao J; Shan C; Yuan Z; Zhao J; Zhu T Emerg Microbes Infect; 2022 Dec; 11(1):1550-1553. PubMed ID: 35604772 [TBL] [Abstract][Full Text] [Related]
27. A new generation of vaccines based on alphavirus self-amplifying RNA. Ballesteros-Briones MC; Silva-Pilipich N; Herrador-Cañete G; Vanrell L; Smerdou C Curr Opin Virol; 2020 Oct; 44():145-153. PubMed ID: 32898764 [TBL] [Abstract][Full Text] [Related]
28. Messenger RNA Vaccine Technology: Success for SARS-CoV-2 and Prospects for an HIV-1 Vaccine. Files JK; Goepfert PA Top Antivir Med; 2024 Apr; 32(2):420-430. PubMed ID: 39141920 [TBL] [Abstract][Full Text] [Related]
29. Nonclinical Safety Assessment of Lipid Nanoparticle-and Emulsion-Based Self-Amplifying mRNA Vaccines in Rats. Donahue DA; Ballesteros C; Maruggi G; Glover C; Ringenberg MA; Marquis M; Ben Abdeljelil N; Ashraf A; Rodriguez LA; Stokes AH Int J Toxicol; 2023; 42(1):37-49. PubMed ID: 36472205 [TBL] [Abstract][Full Text] [Related]
30. Clinical Development of mRNA Vaccines: Challenges and Opportunities. August A; Brito L; Paris R; Zaks T Curr Top Microbiol Immunol; 2022; 440():167-186. PubMed ID: 35906319 [TBL] [Abstract][Full Text] [Related]
31. Polymeric and lipid nanoparticles for delivery of self-amplifying RNA vaccines. Blakney AK; McKay PF; Hu K; Samnuan K; Jain N; Brown A; Thomas A; Rogers P; Polra K; Sallah H; Yeow J; Zhu Y; Stevens MM; Geall A; Shattock RJ J Control Release; 2021 Oct; 338():201-210. PubMed ID: 34418521 [TBL] [Abstract][Full Text] [Related]
32. Oral mRNA Vaccines Against Infectious Diseases- A Bacterial Perspective [Invited]. Jawalagatti V; Kirthika P; Lee JH Front Immunol; 2022; 13():884862. PubMed ID: 35592330 [TBL] [Abstract][Full Text] [Related]
33. mRNA Vaccines: The Dawn of a New Era of Cancer Immunotherapy. Deng Z; Tian Y; Song J; An G; Yang P Front Immunol; 2022; 13():887125. PubMed ID: 35720301 [TBL] [Abstract][Full Text] [Related]
34. Effectiveness of mRNA, protein subunit vaccine and viral vectors vaccines against SARS-CoV-2 in people over 18 years old: a systematic review. Sandoval C; Guerrero D; Muñoz J; Godoy K; Souza-Mello V; Farías J Expert Rev Vaccines; 2023; 22(1):35-53. PubMed ID: 36484136 [TBL] [Abstract][Full Text] [Related]
35. Nucleic acid vaccines: prospects for non-viral delivery of mRNA vaccines. Deering RP; Kommareddy S; Ulmer JB; Brito LA; Geall AJ Expert Opin Drug Deliv; 2014 Jun; 11(6):885-99. PubMed ID: 24665982 [TBL] [Abstract][Full Text] [Related]
36. mRNA vaccines for COVID-19 and diverse diseases. Hussain A; Yang H; Zhang M; Liu Q; Alotaibi G; Irfan M; He H; Chang J; Liang XJ; Weng Y; Huang Y J Control Release; 2022 May; 345():314-333. PubMed ID: 35331783 [TBL] [Abstract][Full Text] [Related]
37. Innovative Strategies to Enhance mRNA Vaccine Delivery and Effectiveness: Mechanisms and Future Outlook. Verma A; Awasthi A Curr Pharm Des; 2024; 30(14):1049-1059. PubMed ID: 38551046 [TBL] [Abstract][Full Text] [Related]
38. RBD-VLP Vaccines Adjuvanted with Alum or SWE Protect K18-hACE2 Mice against SARS-CoV-2 VOC Challenge. Wong TY; Russ BP; Lee KS; Miller OA; Kang J; Cooper M; Winters MT; Rodriguez-Aponte SA; Dalvie NC; Johnston RS; Rader NA; Wong ZY; Cyphert HA; Martinez I; Shaligram U; Batwal S; Lothe R; Chandrasekaran R; Nagar G; Rajurkar M; Rao H; Bevere JR; Barbier M; Love JC; Damron FH mSphere; 2022 Aug; 7(4):e0024322. PubMed ID: 35968964 [TBL] [Abstract][Full Text] [Related]
39. Self-Amplifying RNA: A Second Revolution of mRNA Vaccines against COVID-19. Silva-Pilipich N; Beloki U; Salaberry L; Smerdou C Vaccines (Basel); 2024 Mar; 12(3):. PubMed ID: 38543952 [TBL] [Abstract][Full Text] [Related]
40. mRNA Vaccines in the COVID-19 Pandemic and Beyond. Hogan MJ; Pardi N Annu Rev Med; 2022 Jan; 73():17-39. PubMed ID: 34669432 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]